Abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with poor prognosis due to resistance to conventional chemotherapy and limited efficacy of radiotherapy. There is an urgent need to develop novel biomarkers for early diagnosis, as well as to identify new drug targets for therapeutic interventions.PATIENTS AND METHODS:54 paired HCC samples and 21 normal liver tissues were obtained from West China Hospital of Sichuan University. Informed consent was obtained from all the patients or their relatives prior to analysis, and the project was approved by the Institutional Ethics Committee of Sichuan University. Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC)-based proteomics was employed to profile the differentially expressed proteins between a HepG2 human hepatoma cell line and an immortal hepatic cell line L02. Validation of PGAM1 expression was performed by semi-quantitative RT-PCR, immunoblot and immunohistochemistry using clinical samples. shRNA expressing plasmids specifically targeting PGAM1 were designed and constructed by GenePharma Corporation (Shanghai, China), and were utilized to silence expression of PGAM1 in vitro and in vivo. Cell proliferation was measured by a combination of colony formation assay and Ki67 staining. Apoptosis was examined by flow cytometry and TUNEL assay.RESULTS:A total of 63 dysregulated proteins were identified, including 51 up-regulated proteins, and 12 down-regulated proteins (over 2-fold, p < 0.01). Phosphoglycerate mutase 1 (PGAM1) was found markedly upregulated. Clinico-pathological analysis indicated that overexpression of PGAM1 was associated with 66.7% HCC, and strongly correlated with poor differentiation and decreased survival rates (p < 0.01). shRNAs-mediated repression of PGAM1 expression resulted in significant inhibition in liver cancer cell growth both in vitro and in vivo.CONCLUSION:Our studies suggested that PGAM1 plays an important role in hepatocarcinogenesis, and should be a potential diagnostic biomarker, as well as an attractive therapeutic target for hepatocellular carcinoma.

Preparation of Phosphorylational Polyclonal Antibody to PHF10 and Its Application in Detecting Phosphorylation Status in Gastric Cancer Cells

[Preparation of PHF10 Antibody and Analysis of PHF10 Expression Gastric Cancer Tissues].

PHD Finger Protein 10 Promotes Cell Proliferation by Regulating CD44 Transcription in Gastric Cancer

A novel plant homeodomain finger 10-mediated antiapoptotic mechanism involving repression of caspase-3 in gastric cancer cells.

PHF14 Promotes Cell Proliferation and Migration Through the AKT and ERK1/2 Pathways in Gastric Cancer Cells

M1611 Epigenetic Characterization of a Novel Tumor Suppressor Gene, RNF180, in Gastric Cancer and Its Application in Noninvasive Cancer Detection

A Simple Method for the Preparation of Positive Samples to Preliminarily Determine the Quality of Phosphorylation-Specific Antibody

Preparation of a novel monoclonal antibody against active components of PHA-L from Phaseolus vulgaris and its functional characteristics

Expression, Purification, Antibody Preparation and Preliminary Application of Tumor Protein GOLPH2

Comprehensive analysis of PHF5A as a potential prognostic biomarker and therapeutic target across cancers and in hepatocellular carcinoma

Histone Demethylase PHF8 Promotes Progression and Metastasis of Gastric Cancer.

[Preparation and Detection of Phosphorylated PRAS40 (ser183) Polyclonal Antibody].

Expression and significance of FHIT and TPTEN in gastric carcinoma

PHF10 Inhibits Gastric Epithelium Differentiation and Induces Gastric Cancer Carcinogenesis

Development of IGF Signaling Antibody Arrays for the Identification of Hepatocellular Carcinoma Biomarkers.

Study on the mechanism of macrophages activated by phosphoesterified rehmanniae polysaccharide on human gastric cancer cells

Characterization of phosphoproteins in gastric cancer secretome.

Protein tyrosine-phosphatase expression profiling in gastric cancer tissues

Phosphoserine Phosphatase As a Prognostic Biomarker in Patients with Gastric Cancer and Its Potential Association with Immune Cells

Lower Expression of PH Domain Leucine-Rich Repeat Protein Phosphatase 1 (PHLPP1) Association with Poor Prognosis of Gastric Cancer.

Quantitative Proteomics Identification of Phosphoglycerate Mutase 1 As a Novel Therapeutic Target in Hepatocellular Carcinoma.